Virinchi Ltd. (IN:VIRINCHI)
:VIRINCHI
Top Page
Virinchi Ltd.
(VIRINCHI)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹19.50
▼(-18.10% Downside)
Action:ReiteratedDate:03/28/26
The score is mainly held back by weakening profitability and cash flow (despite a comparatively solid balance sheet), alongside a bearish technical setup with the stock trading below key moving averages. A high P/E and lack of dividend data provide little valuation support, while oversold momentum indicators offer only a modest offset.
Positive Factors
Stable balance sheet
A strong equity base and reasonable leverage provide lasting financial flexibility. Over the next 2-6 months this supports funding of operations, absorbs cyclical shocks, and enables strategic choices (investment, selective M&A, or restructuring) without immediate dependence on volatile external financing.
Negative Factors
Deteriorating profitability
Sharp declines in net profit and lower EBIT/EBITDA margins weaken the firm's ability to reinvest, defend market share, and generate shareholder returns. If margins remain compressed for several quarters, ROE and internal funding capacity will shrink, forcing tougher cost or strategic choices that may harm long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable balance sheet
A strong equity base and reasonable leverage provide lasting financial flexibility. Over the next 2-6 months this supports funding of operations, absorbs cyclical shocks, and enables strategic choices (investment, selective M&A, or restructuring) without immediate dependence on volatile external financing.
Read all positive factors
Virinchi Ltd. (VIRINCHI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.92B
Dividend YieldN/A
Average Volume (3M)49.69K
Price to Earnings (P/E)41.4
Beta (1Y)1.31
Revenue Growth-1.40%
EPS Growth-238.47%
CountryIN
Employees1,033
SectorHealthcare
Sector Strength45
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.16
Shares Outstanding102,646,900
10 Day Avg. Volume10,427
30 Day Avg. Volume49,685
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)0.47
Price to Sales (P/S)0.74
P/FCF Ratio-8.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.4
Revenue Forecast (FY)₹4.14B
Virinchi Ltd. Business Overview & Revenue Model
Company Description
Virinchi Limited provides information technology (IT) products and services worldwide. The company operates through Development of Computer Software and Services, IT Enabled Services, and Healthcare Services segments. It offers QFund, an IT soluti...
How the Company Makes Money
null...
Virinchi Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.93B | 3.01B | 3.00B | 3.12B | 3.64B | 3.54B |
| Gross Profit | 1.70B | 1.35B | 1.79B | 1.93B | 3.36B | 3.31B |
| EBITDA | 865.78M | 963.86M | 1.14B | 1.11B | 1.04B | 1.02B |
| Net Income | -137.78M | 7.24M | 137.03M | 128.49M | 143.05M | 27.46M |
Balance Sheet | ||||||
| Total Assets | 8.31B | 8.47B | 8.51B | 7.87B | 7.03B | 6.87B |
| Cash, Cash Equivalents and Short-Term Investments | 55.95M | 77.58M | 200.25M | 307.08M | 366.00M | 190.21M |
| Total Debt | 2.95B | 2.92B | 3.30B | 3.17B | 2.76B | 2.61B |
| Total Liabilities | 3.72B | 3.73B | 3.97B | 3.80B | 3.33B | 3.12B |
| Stockholders Equity | 4.61B | 4.76B | 4.55B | 4.08B | 3.71B | 3.76B |
Cash Flow | ||||||
| Free Cash Flow | 22.61M | -253.64M | 26.54M | -377.22M | 525.18M | -1.04B |
| Operating Cash Flow | 65.92M | 536.65M | 1.16B | 987.00M | 846.73M | 498.55M |
| Investing Cash Flow | -38.08M | -778.34M | -1.15B | -1.37B | -336.79M | -1.54B |
| Financing Cash Flow | -49.47M | 119.01M | -127.06M | 323.82M | -334.14M | 1.15B |
Virinchi Ltd. Technical Analysis
Neutral
23.81
Price Trends
18.75
Positive
20.96
Negative
24.21
Negative
Market Momentum
-0.45
Negative
59.08
Neutral
87.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIRINCHI, the sentiment is Neutral. The current price of 23.81 is above the 20-day moving average (MA) of 16.72, above the 50-day MA of 18.75, and below the 200-day MA of 24.21, indicating a neutral trend. The MACD of -0.45 indicates Negative momentum. The RSI at 59.08 is Neutral, neither overbought nor oversold. The STOCH value of 87.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:VIRINCHI.
Virinchi Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹3.43B | 48.53 | ― | ― | -0.77% | 2055.99% | |
64 Neutral | ₹1.46B | 21.48 | ― | ― | 14.53% | -10.49% | |
59 Neutral | ₹1.92B | 41.39 | ― | ― | -1.40% | -238.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹1.95B | 84.53 | ― | ― | -17.47% | -50.07% | |
45 Neutral | ₹1.27B | -11.90 | ― | ― | -46.31% | -26.28% |
* Healthcare Sector Average
IN:VIRINCHI
Virinchi Ltd.
18.75
-2.87
-13.27%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
68.65
15.76
29.80%
IN:ALPA
Alpa Laboratories Limited
69.53
-38.92
-35.89%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
145.00
70.10
93.59%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
58.97
-17.53
-22.92%
IN:NATCAPSUQ
Natural Capsules Limited
153.60
-64.35
-29.53%
Virinchi Ltd. Corporate Events
Virinchi Boosts Equity Capital with Preferential Allotment to Promoter Group
Apr 10, 2026
Virinchi Limited has allotted 850,000 equity shares at an issue price of Rs.28 per share upon conversion of warrants previously issued on a preferential basis to promoter group entity Vivo Bio Tech Limited. Following this allotment, the company...
Virinchi Limited Posts Higher Profit and Revenue in Q3 FY2025-26 Unaudited Results
Feb 4, 2026
Virinchi Limited reported strong unaudited standalone financial results for the quarter and nine months ended December 31, 2025, with quarterly revenue from operations rising to Rs 4,283.70 lakh and total income reaching Rs 4,846.73 lakh. Profit b...
Virinchi Board Clears December Quarter Financials with Profit Uptick
Feb 4, 2026
Virinchi’s board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with standalone revenue rising to Rs4,283.7 lakh and quarterly profit after tax strengthening to Rs...
Virinchi Board Seeks Shareholder Nod for Promoter’s Investment in Healthcare Subsidiary
Jan 20, 2026
Virinchi Limited’s board has approved seeking shareholder approval via postal ballot for a preferential allotment of convertible equity warrants to promoter Viswanath Kompella in its material subsidiary, Virinchi Health Care Private Limited,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.